Niacin/Laropiprant therapy reduces serum Lipoprotein (a) levels (Abstract/Comunicazione in atti di convegno)

Type
Label
  • Niacin/Laropiprant therapy reduces serum Lipoprotein (a) levels (Abstract/Comunicazione in atti di convegno) (literal)
Anno
  • 2011-01-01T00:00:00+01:00 (literal)
Alternative label
  • M. Puntoni, F. Bigazzi, F. Sbrana, M. Pianelli, R. Luciani, A. Ragusa, S. Vicari, E. Grisanti, T. Sampietro (2011)
    Niacin/Laropiprant therapy reduces serum Lipoprotein (a) levels
    in 25. congresso nazionale SISA, Roma, 30 novembre - 3 dicembre 2011
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • M. Puntoni, F. Bigazzi, F. Sbrana, M. Pianelli, R. Luciani, A. Ragusa, S. Vicari, E. Grisanti, T. Sampietro (literal)
Pagina inizio
  • 89 (literal)
Pagina fine
  • 90 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni
  • ID_PUMA: cnr.ifc/2011-B6-002 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://www.sisa.it/index.php?class=Comp&className=Content&op=Show¶m=cid,367,preview,0 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 2 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 3 (literal)
Note
  • Abstract (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Fondazione CNR, Regione Toscana \"Gabriele Monasterio\", Pisa, Italy ; CNR Institute of Clinical Physiology of Pisa, Italy (literal)
Titolo
  • Niacin/Laropiprant therapy reduces serum Lipoprotein (a) levels (literal)
Abstract
  • Background. High plasma levels of lipoprotein(a) [Lp(a)] are risk factor for ischemic heart disease, stroke and are associated with the severity of coronary atherosclerosis. We sought to see whether extended-release niacin/laropiprant (ERN/LRPN) could lower Lp(a) levels. Material and Methods. We followed-up for 8 weeks a group of 16 patients (mean age 55±12 years, 66% male) with high Lp(a) levels and chronic coronary artery disease. ERN/LRPN was added on top of maximally tolerated lipid-lowering therapy, administered at the dose of 1 gr/day for the first 4 weeks and then at 2 gr/day for the remaining period. Clinical examination and blood sampling (including lipid profile, renal and hepatic function) were performed at baseline, after 4 and 8 weeks, and in the case of adverse manifestations. Results. During follow-up, 4 patients discontinued therapy due to side effects (headache, asthenia, and gastrointestinal disorders in 2 patients, eruptive skin rash in 1 patient, onset of diabetes mellitus in 1 patient). In the remaining 12 patients, a significant reduction of Lp(a) serum concentrations was observed: Lp(a) levels was reduced of 20.6% after 4 week (p<0.0005) and of 36.0% after 8 week (p<0.005) respect to basal serum concentrations. After two months of therapy, in 36% of patients Lp(a) values were normalized (i.e <60 mg/dl). These results are obtained in the absence of substantial changes in other laboratory analyses (with the exception of a non-significant increase in uric acid). Conclusions. These results show that the ERN/LRPN therapy significant reduces Lp(a) levels, thus representing a new treatment option in patients with high Lp(a) levels and coronary artery disease, although the high frequency of collateral effects may be a limitation. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it